Home > Medical Reference > Complementary Medicine

Hydrocortisone


Pronunciation

 (hye droe KOR ti sone)


U.S. Brand Names

 Anucort-HC®; Anusol-HC®; Anusol® HC-1 [OTC]; Aquanil™ HC [OTC]; Beta-HC®; Caldecort® [OTC]; Cetacort®; Colocort®; CortaGel® Maximum Strength [OTC] [DSC]; Cortaid® Intensive Therapy [OTC]; Cortaid® Maximum Strength [OTC]; Cortaid® Sensitive Skin [OTC]; Cortef®; Corticool® [OTC]; Cortifoam®; Cortizone®-10 Maximum Strength [OTC]; Cortizone®-10 Plus Maximum Strength [OTC]; Cortizone® 10 Quick Shot [OTC]; Dermarest Dricort® [OTC]; Dermtex® HC [OTC]; EarSol® HC; Hemril®-30; Hydrocortone® [DSC]; HydroZone Plus [OTC]; Hytone®; IvySoothe® [OTC]; LactiCare-HC® [DSC]; Locoid®; Locoid Lipocream®; Nupercainal® Hydrocortisone Cream [OTC]; Nutracort®; Pandel®; Post Peel Healing Balm [OTC]; Preparation H® Hydrocortisone [OTC]; Proctocort®; ProctoCream® HC; Procto-Kit™; Procto-Pak™; Proctosert; Proctosol-HC®; Proctozone-HC™; Sarnol®-HC [OTC]; Solu-Cortef®; Summer's Eve® SpecialCare™ Medicated Anti-Itch Cream [OTC]; Texacort®; Westcort®


Synonyms

 A-hydroCort; Compound F; Cortisol; Hemorrhoidal HC; Hydrocortisone Acetate; Hydrocortisone Butyrate; Hydrocortisone Probutate; Hydrocortisone Sodium Succinate; Hydrocortisone Valerate


Generic Available

 Yes: Excludes acetate foam, butyrate cream and ointment, gel as base, otic drops as base, probutate cream, sodium succinate injection


Canadian Brand Names

 Aquacort®; Cortamed®; Cortate®; Cortef®; Cortenema®; Cortifoam™; Cortoderm; Emo-Cort®; Hycort™; Hyderm; HydroVal®; Locoid®; Prevex® HC; Sarna® HC; Solu-Cortef®; Westcort®


Use

 Management of adrenocortical insufficiency; relief of inflammation of corticosteroid-responsive dermatoses (low and medium potency topical corticosteroid); adjunctive treatment of ulcerative colitis


Use - Dental

 Treatment of a variety of oral diseases of allergic, inflammatory, or autoimmune origin


Pregnancy Risk Factor

 C


Pregnancy Implications

 There are no adequate and well-controlled studies in pregnant women. Corticosteroid use has been associated with cleft palate, neonatal adrenal suppression, low birth weight, and cataracts in the infant; including cases associated with topical administration. Use only if potential benefit to the mother exceeds the potential risk to the fetus. Avoid high doses or prolonged use.


Lactation

 Excretion in breast milk unknown/use caution


Contraindications

 Hypersensitivity to hydrocortisone or any component of the formulation; serious infections, except septic shock or tuberculous meningitis; viral, fungal, or tubercular skin lesions


Warnings/Precautions

Use with caution in patients with hyperthyroidism, cirrhosis, nonspecific ulcerative colitis, hypertension, osteoporosis, thromboembolic tendencies, CHF, convulsive disorders, myasthenia gravis, thrombophlebitis, peptic ulcer, diabetes, glaucoma, cataracts, or tuberculosis. Use caution in hepatic impairment.

May cause HPA axis suppression. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term therapy or with stress; young pediatric patients may be more susceptible to adrenal axis suppression from topical therapy. Avoid use of topical preparations with occlusive dressings or on weeping or exudative lesions.

Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly, in the smallest possible dose, and for the shortest possible time


Adverse Reactions

Systemic:

>10%:

Central nervous system: Insomnia, nervousness

Gastrointestinal: Increased appetite, indigestion

1% to 10%:

Dermatologic: Hirsutism

Endocrine & metabolic: Diabetes mellitus

Neuromuscular & skeletal: Arthralgia

Ocular: Cataracts

Respiratory: Epistaxis

<1%: Hypertension, edema, euphoria, headache, delirium, hallucinations, seizure, mood swings, acne, dermatitis, skin atrophy, bruising, hyperpigmentation, hypokalemia, hyperglycemia, Cushing's syndrome, sodium and water retention, bone growth suppression, amenorrhea, peptic ulcer, abdominal distention, ulcerative esophagitis, pancreatitis, muscle wasting, hypersensitivity reactions, immunosuppression

Topical:

>10%: Dermatologic: Eczema (12.5%)

1% to 10%: Dermatologic: Pruritus (6%), stinging (2%), dry skin (2%)

<1%: Allergic contact dermatitis, burning, dermal atrophy, folliculitis, HPA axis suppression, hypopigmentation; metabolic effects (hyperglycemia, hypokalemia); striae


Overdosage/Toxicology

 When consumed in high doses for prolonged periods, systemic hypercorticism and adrenal suppression may occur. In those cases, discontinuation of the corticosteroid should be done judiciously.


Drug Interactions

 Substrate of CYP3A4 (minor); Induces CYP3A4 (weak)

Decreased effect:

Insulin decreases hypoglycemic effect

Phenytoin, phenobarbital, ephedrine, and rifampin increase metabolism of hydrocortisone and decrease steroid blood level

Increased toxicity:

Oral anticoagulants change prothrombin time

Potassium-depleting diuretics increase risk of hypokalemia

Cardiac glucosides increase risk of arrhythmias or digitalis toxicity secondary to hypokalemia


Ethanol/Nutrition/Herb Interactions

Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).

Food: Hydrocortisone interferes with calcium absorption.

Herb/Nutraceutical: St John's wort may decrease hydrocortisone levels. Avoid cat's claw, echinacea (have immunostimulant properties).


Stability

 Store at controlled room temperature 20°C to 25°C (59°F to 86°F). Hydrocortisone sodium phosphate and hydrocortisone sodium succinate are clear, light yellow solutions which are heat labile.

Sodium succinate: Reconstitute 100 mg vials with bacteriostatic water (not >2 mL). Act-O-Vial (self-contained powder for injection plus diluent) may be reconstituted by pressing the activator to force diluent into the powder compartment. Following gentle agitation, solution may be withdrawn via syringe through a needle inserted into the center of the stopper. May be administered (I.V. or I.M.) without further dilution. After initial reconstitution, hydrocortisone sodium succinate solutions are stable for 3 days at room temperature or under refrigeration when protected from light. Stability of parenteral admixture (Solu-Cortef®) at room temperature (25°C) and at refrigeration temperature (4°C) is concentration-dependent:

Stability of concentration 1 mg/mL: 24 hours

Stability of concentration 2 mg/mL to 60 mg/mL: At least 4 hours

Solutions for I.V. infusion: Reconstituted solutions may be added to an appropriate volume of compatible solution for infusion. Concentration should generally not exceed 1 mg/mL. However, in cases where administration of a small volume of fluid is desirable, 100-3000 mg may be added to 50 mL of D5W or NS (stability limited to 4 hours).


Compatibility

Hydrocortisone sodium phosphate: Stable in D5W, NS, fat emulsion 10%

Y-site administration: Compatible: Allopurinol, amifostine, aztreonam, cefepime, cladribine, clarithromycin, docetaxel, etoposide, famotidine, filgrastim, fluconazole, fludarabine, gemcitabine, granisetron, melphalan, ondansetron, paclitaxel, piperacillin/tazobactam, teniposide, thiotepa, vinorelbine. Incompatible: Sargramostim

Compatibility in syringe: Compatible: Metoclopramide. Incompatible: Doxapram

Compatibility when admixed: Compatible: Amikacin, amphotericin B, amphotericin B with heparin, bleomycin, dacarbazine, metaraminol, sodium bicarbonate, verapamil. Variable (consult detailed reference): Mitoxantrone

Hydrocortisone sodium succinate: Stable in dextran 6% in dextrose, dextran 6% in NS, D5LR, D5 1 /4NS, D5 1 /2NS, D5NS, D5W, D10W, D20W, LR, 1 /2NS, NS, fat emulsion 10%

Y-site administration: Compatible: Acyclovir, allopurinol, amifostine, aminophylline, amphotericin B cholesteryl sulfate complex, ampicillin, amsacrine, atracurium, atropine, aztreonam, betamethasone sodium phosphate, calcium gluconate, cefepime, chlordiazepoxide, chlorpromazine, cisatracurium, cladribine, cyanocobalamin, cytarabine, dexamethasone sodium phosphate, digoxin, diphenhydramine, docetaxel, dopamine, doxorubicin liposome, droperidol, droperidol and fentanyl, edrophonium, enalaprilat, epinephrine, esmolol, estrogens (conjugated), ethacrynate sodium, etoposide, famotidine, fentanyl, filgrastim, fludarabine, fluorouracil, foscarnet, furosemide, gatifloxacin, gemcitabine, granisetron, heparin, hydralazine, inamrinone, insulin (regular), isoproterenol, kanamycin, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, menadiol sodium diphosphate, meperidine, methoxamine, methylergonovine, minocycline, morphine, neostigmine, norepinephrine, ondansetron, oxacillin, oxytocin, paclitaxel, pancuronium, penicillin G potassium, pentazocine, phytonadione, piperacillin/tazobactam, procainamide, prochlorperazine edisylate, propofol, propranolol, pyridostigmine, remifentanil, scopolamine, sodium bicarbonate, succinylcholine, tacrolimus, teniposide, theophylline, thiotepa, trimethaphan camsylate, trimethobenzamide, vecuronium, vinorelbine. Incompatible: Ciprofloxacin, diazepam, ergotamine, idarubicin, midazolam, phenytoin, sargramostim. Variable (consult detailed reference): Diltiazem, methylprednisolone sodium succinate, promethazine

Compatibility in syringe: Compatible: Diatrizoate meglumine 52%, diatrizoate sodium 8%, diatrizoate sodium 60%, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3%, ioxaglate sodium 19.6%, metoclopramide, thiopental. Incompatible: Doxapram

Compatibility when admixed: Compatible: Amikacin, aminophylline, amphotericin B, calcium chloride, calcium gluconate, chloramphenicol, clindamycin, corticotropin, daunorubicin, diphenhydramine, dopamine, erythromycin lactobionate, floxacillin, lidocaine, magnesium sulfate, mephentermine, metronidazole, metronidazole with sodium bicarbonate, mitomycin, mitoxantrone, norepinephrine, penicillin G potassium, penicillin G sodium, piperacillin, polymyxin B sulfate, potassium chloride, procaine, sodium bicarbonate, theophylline, thiopental, vancomycin, verapamil, vitamin B complex with C. Incompatible: Aminophylline with cephalothin, bleomycin, colistimethate, ephedrine, hydralazine, nafcillin, pentobarbital, phenobarbital, prochlorperazine edisylate, promethazine. Variable (consult detailed reference): Amobarbital, ampicillin, cytarabine, dimenhydrinate, furosemide, heparin, kanamycin, metaraminol


Mechanism of Action

 Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability


Pharmacodynamics/Kinetics

Onset of action:

Hydrocortisone acetate: Slow

Hydrocortisone sodium succinate (water soluble): Rapid

Duration: Hydrocortisone acetate: Long

Absorption: Rapid by all routes, except rectally

Metabolism: Hepatic

Half-life elimination: Biologic: 8-12 hours

Excretion: Urine (primarily as 17-hydroxysteroids and 17-ketosteroids)


Dosage

 Dose should be based on severity of disease and patient response

Acute adrenal insufficiency: I.M., I.V.:

Infants and young Children: Succinate: 1-2 mg/kg/dose bolus, then 25-150 mg/day in divided doses every 6-8 hours

Older Children: Succinate: 1-2 mg/kg bolus then 150-250 mg/day in divided doses every 6-8 hours

Adults: Succinate: 100 mg I.V. bolus, then 300 mg/day in divided doses every 8 hours or as a continuous infusion for 48 hours; once patient is stable change to oral, 50 mg every 8 hours for 6 doses, then taper to 30-50 mg/day in divided doses

Chronic adrenal corticoid insufficiency: Adults: Oral: 20-30 mg/day

Anti-inflammatory or immunosuppressive:

Infants and Children:

Oral: 2.5-10 mg/kg/day or 75-300 mg/m 2 /day every 6-8 hours

I.M., I.V.: Succinate: 1-5 mg/kg/day or 30-150 mg/m 2 /day divided every 12-24 hours

Adolescents and Adults: Oral, I.M., I.V.: Succinate: 15-240 mg every 12 hours

Congenital adrenal hyperplasia: Oral: Initial: 10-20 mg/m 2 /day in 3 divided doses; a variety of dosing schedules have been used. Note: Inconsistencies have occurred with liquid formulations; tablets may provide more reliable levels. Doses must be individualized by monitoring growth, bone age, and hormonal levels. Mineralocorticoid and sodium supplementation may be required based upon electrolyte regulation and plasma renin activity.

Physiologic replacement: Children:

Oral: 0.5-0.75 mg/kg/day or 20-25 mg/m 2 /day every 8 hours

I.M.: Succinate: 0.25-0.35 mg/kg/day or 12-15 mg/m 2 /day once daily

Shock: I.M., I.V.: Succinate:

Children: Initial: 50 mg/kg, then repeated in 4 hours and/or every 24 hours as needed

Adolescents and Adults: 500 mg to 2 g every 2-6 hours

Status asthmaticus: Children and Adults: I.V.: Succinate: 1-2 mg/kg/dose every 6 hours for 24 hours, then maintenance of 0.5-1 mg/kg every 6 hours

Adults:

Rheumatic diseases:

Intralesional, intra-articular, soft tissue injection: Acetate:

Large joints: 25 mg (up to 37.5 mg)

Small joints: 10-25 mg

Tendon sheaths: 5-12.5 mg

Soft tissue infiltration: 25-50 mg (up to 75 mg)

Bursae: 25-37.5 mg

Ganglia: 12.5-25 mg

Stress dosing (surgery) in patients known to be adrenally-suppressed or on chronic systemic steroids: I.V.:

Minor stress (ie, inguinal herniorrhaphy): 25 mg/day for 1 day

Moderate stress (ie, joint replacement, cholecystectomy): 50-75 mg/day (25 mg every 8-12 hours) for 1-2 days

Major stress (pancreatoduodenectomy, esophagogastrectomy, cardiac surgery): 100-150 mg/day (50 mg every 8-12 hours) for 2-3 days

Dermatosis: Children >2 years and Adults: Topical: Apply to affected area 2-4 times/day (Buteprate: Apply once or twice daily). Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.

Ulcerative colitis: Adults: Rectal: 10-100 mg 1-2 times/day for 2-3 weeks


Administration

Oral: Administer with food or milk to decrease GI upset

Parenteral: Hydrocortisone sodium succinate may be administered by I.M. or I.V. routes

I.V. bolus: Dilute to 50 mg/mL and administer over 30 seconds to several minutes (depending on the dose)

I.V. intermittent infusion: Dilute to 1 mg/mL and administer over 20-30 minutes

Topical: Apply a thin film to clean, dry skin and rub in gently


Monitoring Parameters

 Blood pressure, weight, serum glucose, and electrolytes


Reference Range

 Therapeutic: AM: 5-25 mcg/dL (SI: 138-690 nmol/L), PM: 2-9 mcg/dL (SI: 55-248 nmol/L) depending on test, assay


Dietary Considerations

 Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B6, C, D, folate, calcium, zinc, phosphorus, and decreased sodium. Sodium content of 1 g (sodium succinate injection): 47.5 mg (2.07 mEq)


Patient Education

 Systemic: Take as directed; do not increase doses and do not stop abruptly without consulting prescribed. Dosage of systemic hydrocortisone is usually tapered off gradually. Take oral dose with food to reduce GI upset. Avoid alcohol. Hydrocortisone may cause immunosuppression and mask symptoms of infection; avoid exposure to contagion and notify prescriber of any signs of infection (eg, fever, chills, sore throat, injury) and notify dentist or surgeon (if necessary) that you are taking this medication. You may experience increased appetite, indigestion, or increased nervousness. Report any sudden weight gain (>5 lb/week), swelling of extremities or respiratory difficulty, abdominal pain, severe vomiting, black or tarry stools, fatigue, anorexia, weakness, or unusual mood swings. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to become pregnant. Consult prescriber if breast-feeding.

Topical: Before applying, wash area gently and thoroughly. Apply a thin film to cleansed area and rub in gently until medication vanishes. Avoid use of occlusive dressings over topical application unless directed by a physician. Avoid use on weeping or exudative lesions. Avoid exposing affected area to sunlight; you will be more sensitive and severe sunburn may occur. Consult prescriber if breast-feeding.

Rectal: Gently insert suppository as high as possible with gloved finger while lying down. Avoid injury with long or sharp fingernails. Remain in resting position for 10 minutes after insertion.


Additional Information

 Hydrocortisone base topical cream, lotion, and ointments in concentrations of 0.25%, 0.5%, and 1% may be OTC or prescription depending on the product labeling.


Anesthesia and Critical Care Concerns/Other Considerations

 Hydrocortisone is a long-acting corticosteroid with minimal sodium-retaining potential.

Neuromuscular Effects: ICU-acquired paresis was recently studied in 5 ICUs (3 medical and 2 surgical ICUs) at 4 French hospitals. All ICU patients without pre-existing neuromuscular disease admitted from March 1999 through June 2000 were evaluated (De Jonghe B, 2002). Each patient had to be mechanically ventilated for 7 days and was screened daily for awakening. The first day the patient was considered awake was Study Day 1. Patients with severe muscle weakness on Study Day 7 were considered to have ICU-acquired paresis. Among the 95 patients who were evaluable, about 25% developed ICU-acquired paresis. Independent predictors included: female gender, the number of days with 2 organ dysfunction, and administration of corticosteroids. Further studies may be required to verify and characterize the association between the development of ICU-acquired paresis and use of corticosteroids. Concurrent use of a corticosteroid and muscle relaxant appear to increase the risk of certain ICU myopathies; avoid or administer the corticosteroid at the lowest dose possible.

Adrenal Insufficiency: Patients will often have steroid-induced adverse effects on glucose tolerance and lipid profiles. When discontinuing steroid therapy in patients on long-term steroid supplementation, it is important that the steroid therapy be discontinued gradually. Abrupt withdrawal may result in adrenal insufficiency with hypotension and hyperkalemia. Patients on long-term steroid supplementation will require higher corticosteroid doses when subject to stress (ie, trauma, surgery, severe infection). Guidelines for glucocorticoid replacement during various surgical procedures has been published (Salem M, 1994, Coursin DB, 2002).

Septic Shock: A recent randomized, double-blind, placebo controlled trial assessed whether low dose corticosteroid administration could improve 28-day survival in patients with septic shock and relative adrenal insufficiency. Relative adrenal insufficiency was defined as an inappropriate response to corticotropin administration (increase of serum cortisol of 9 mcg/dL from baseline). Cortisol levels were drawn immediately before corticotropin administration and 30 to 60 minutes afterwards. Three hundred adult septic shock patients requiring mechanical ventilation and vasopressor support were randomized to either hydrocortisone (50 mg IVP every 6 hours) and fludrocortisone (50 mcg tablet daily via nasogastric tube) or matching placebos for 7 days. In patients who did not appropriately respond to corticotropin (nonresponders), there were significantly fewer deaths in the active treatment group. Vasopressor therapy was withdrawn more frequently in this subset of the active treatment group. Adverse events were similar in both groups. Patients who lack adrenal reserve and thus have relative adrenal insufficiency during the stress of septic shock may benefit from physiologic steroid replacement. However, there was a trend for increased mortality in patients who responded to the corticotropin test (increase serum cortisol >9 mcg/dL from baseline). These patients may not benefit from physiologic steroid replacement. Further study is required to better characterize the patient populations who may benefit.


Cardiovascular Considerations

 Long-term steroid therapy is associated with a fluid retention and hypertension. Glucocorticoid agents have some mineralocorticoid activity with consequent hemodynamic effects. Patients will often have steroid-induced adverse effects on glucose tolerance and lipid profiles. In discontinuing steroid therapy in patients on long-term steroid supplementation, it is important that steroid therapy be discontinued gradually. Abrupt withdrawal may result in adrenal insufficiency with hypotension and hyperkalemia.

Oral and intravenous steroid therapy in patients with heart failure should be administered cautiously with special attention given to signs and symptoms of fluid retention.


Dental Health: Effects on Dental Treatment

 No significant effects or complications reported


Dental Health: Vasoconstrictor/Local Anesthetic Precautions

 No information available to require special precautions


Mental Health: Effects on Mental Status

 Insomnia and nervousness are common; rare reports of delirium, euphoria, hallucinations, and mood swings


Mental Health: Effects on Psychiatric Treatment

 Barbiturates may increase the metabolism of hydrocortisone; lithium has been used to treat mood swings associated with hydrocortisone


Dosage Forms

 [DSC] = Discontinued product

Aerosol, rectal, as acetate (Cortifoam®): 10% (15 g) [90 mg/applicator]

Cream, rectal, as acetate (Nupercainal® Hydrocortisone Cream): 1% (30 g) [strength expressed as base]

Cream, rectal, as base:

Cortizone®-10: 1% (30g) [contains aloe]

Preparation H® Hydrocortisone: 1% (27 g)

Cream, topical, as acetate: 0.5% (9 g, 30 g, 60 g) [available with aloe]; 1% (30 g, 454 g) [available with aloe]

Cream, topical, as base: 0.5% (30 g); 1% (1.5 g, 30 g, 114 g, 454 g); 2.5% (20 g, 30 g, 454 g)

Anusol-HC®: 2.5% (30 g) [contains benzyl alcohol]

Caldecort®: 1% (30 g) [contains aloe vera gel]

Cortaid® Intensive Therapy: 1% (60 g)

Cortaid® Maximum Strength: 1% (15 g, 30 g, 40 g, 60 g) [contains aloe vera gel and benzyl alcohol]

Cortaid® Sensitive Skin: 0.5% (15 g) [contains aloe vera gel]

Cortizone®-10 Maximum Strength: 1% (15 g, 30 g, 60 g) [contains aloe]

Cortizone®-10 Plus Maximum Strength: 1% (30 g, 60 g) [contains vitamins A, D, E and aloe]

Dermarest® Dri-Cort: 1% (15 g, 30 g)

HydroZone Plus, Proctocort®, Procto-Pak™: 1% (30 g)

Hytone®: 2.5% (30 g, 60 g)

IvySoothe™: 1% (30 g) [contains aloe]

Post Peel Healing Balm: 1% (23 g)

ProctoCream® HC: 2.5% (30 g) [contains benzyl alcohol]

Procto-Kit™: 1% (30 g) [packaged with applicator tips and finger cots]; 2.5% (30g) [packaged with applicator tips and finger cots]

Proctosol-HC®, Proctozone-HC™: 2.5% (30 g)

Summer's Eve® SpecialCare™ Medicated Anti-Itch Cream: 1% (30 g)

Cream, topical, as butyrate (Locoid®, Locoid Lipocream®): 0.1% (15 g, 45 g)

Cream, topical, as probutate (Pandel®): 0.1% (15 g, 45 g, 80 g)

Cream, topical, as valerate (Westcort®): 0.2% (15 g, 45 g, 60 g)

Gel, topical, as base:

Corticool®: 1% (45 g)

Cortagel® Maximum Strength: 1% (15 g, 30 g) [contains aloe vera gel] [DSC]

Injection, powder for reconstitution, as sodium succinate (Solu-Cortef®): 100 mg, 250 mg, 500 mg, 1 g [diluent contains benzyl alcohol; strength expressed as base]

Lotion, topical, as base: 1% (120 mL); 2.5% (60 mL)

Aquanil™ HC: 1% (120 mL)

Beta-HC®, Cetacort®, Sarnol®-HC: 1% (60 mL)

HydroZone Plus: 1% (120 mL)

Hytone®: 2.5% (60 mL)

LactiCare-HC®: 1% (120 mL); 2.5% (60 mL, 120 mL) [DSC]

Nutracort®: 1% (60 mL, 120 mL); 2.5% (60 mL, 120 mL)

Ointment, topical, as acetate: 1% (30 g) [strength expressed as base; available with aloe]

Anusol® HC-1: 1% (21 g) [strength expressed as base]

Cortaid® Maximum Strength: 1% (15 g, 30 g) [strength expressed as base]

Ointment, topical, as base: 0.5% (30 g); 1% (30 g, 454 g); 2.5% (20 g, 30 g, 454 g)

Cortizone®-10 Maximum Strength: 1% (30 g, 60 g)

Hytone®: 2.5% (30 g)

Ointment, topical, as butyrate (Locoid®): 0.1% (15 g, 45 g)

Ointment, topical, as valerate (Westcort®): 0.2% (15 g, 45 g, 60 g)

Solution, otic, as base (EarSol® HC): 1% (30 mL) [contains alcohol 44%, benzyl benzoate, yerba santa]

Solution, topical, as base (Texacort®): 2.5% (30 mL) [contains alcohol]

Solution, topical, as butyrate (Locoid®): 0.1% (20 mL, 60 mL) [contains alcohol 50%]

Solution, topical spray, as base:

Cortaid® Intensive Therapy: 1% (60 mL) [contains alcohol]

Cortizone® 10 Quick Shot: 1% (44 mL) [contains benzyl alcohol]

Dermtex® HC: 1% (52 mL) [contains menthol 1%]

Suppository, rectal, as acetate: 25 mg (12s, 24s, 100s)

Anucort™ HC: 25 mg (12s, 24s, 100s)

Anusol-HC®, Proctosol-HC®: 25 mg (12s, 24s)

Encort™: 30 mg (12s)

Hemril®-30, Proctocort®, Proctosert: 30 mg (12s, 24s)

Suspension, rectal, as base: 100 mg/60 mL (7s)

Colocort®: 100 mg/60 mL (1s, 7s)

Tablet, as base: 20 mg

Cortef®: 5 mg, 10 mg, 20 mg

Hydrocortone®: 10 mg [DSC]


References

Abraham E and Evans T, "Corticosteroids and Septic Shock [editorial]," JAMA , 2002, 288(7):886-7.

Annane D, Sebille V, Charpentier C, et al, "Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock," JAMA , 2002, 288(7):862-71.

Cooper MS and Stewart PM, "Corticosteroid Insufficiency in Acutely Ill Patients," N Engl J Med , 2003, 348(8):727-34.

Coursin DB and Wood KE, "Corticosteroid Supplementation for Adrenal Insufficiency," JAMA , 2002, 287(2):236-40.

de Jonghe B, Sharshar T, Lefaucheur JP, et al, "Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study," JAMA , 2002, 288(22):2859-67.

Gamsu HR, Mullinger BM, Donnai P, et al, "Antenatal Administration of Betamethasone to Prevent Respiratory Distress Syndrome in Preterm Infants: Report of a UK Multicentre Trial," Br J Obstet Gynaecol , 1989, 96(4):401-10.

Hotchkiss RS and Karl IE, "The Pathophysiology and Treatment of Sepsis," N Engl J Med , 2003, 348(2):138-50.

Liggins GC and Howie RN, "A Controlled Trial of Antepartum Glucocorticoid Treatment of Respiratory Distress Syndrome in Premature Infants," Pediatrics , 1972, 50:515-25.

Salem M, Tainsh RE Jr, Bromberg J, et al, "Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem," Ann Surg , 1994, 219(4):416-25.

"Technical Report: Congenital Adrenal Hyperplasia," American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics, Pediatrics , 2000, 106(6):1511-8.


International Brand Names

 Alfacort® (AR); Alphaderm® (IE, LU); Aquacort® (CA); Aquanil HC® (MX); BK Lotion® (NZ); Calmurid® (CL); Cortamed® (CA); Cortate® (CA); Cortef® (CA, HR, HU, RU); Cortemen® (AR); Cortenema® (CA); Cortenem® (AR); Cortifoam™ (CA); Cortisol L.CH.® (CL); Cortizone® (IL); Cortoderm (CA); Cortopin® (IE); Cortril® (BE, LU); Cotson® (BD); Cremicort-H® (BE); Cutaderm® (ZA); Dermacort Hydrocortisone® (GB); Derm-Aid® (AU, CY, SG); Dermallerg-ratiopharm® (DE); Dermaspraid® (FR); Dermocortal® (IT); DermoPosterisan® (DE); Dioderm® (GB, IE); DP Hydrocortison Cream® (NZ); DP Lotion HC® (NZ); Efcortelan® (GB, HK, KW); Egocort Cream 1%® (AU, CY, HK, JO, KW, MT, NZ, SG); Emo-Cort® (CA); Fenistil Hydrocort® (DE); Fenuril®-Hydrokortison (SE); Ficortril® [extern.] (SE); Foille® (IT); HC-cream® (IE); Hidalone® (PT); Hidroaltesona® (ES); Hidrocort® (AR); Hidrocortisona Biocrom® (AR); Hidrocortisona Fabra® (AR); Hidrokortizon® (YU); Hidrotisona® (AR); Hycor Eye Drops® (AU); Hycort™ (CA); Hyderm (CA); Hydracort® (FR); Hydrocortison® (BG, FI, HU, YU); Hydrocortison Dispersa® (LU); Hydrocortisone® (CY, IL, NZ); Hydrocortisone Erfa® (BE); Hydrocortisone Kerapharm® (FR); Hydrocortisone Roussel® (BE, FR, LU); Hydrocortison Essex® (FI); Hydrocortison Galen® (DE); Hydrocortison Heumann® (DE); Hydrocortison Hoechst® (DE); Hydrocortison Jenapharm® (CZ, DE); Hydrocortison Leiras® (FI); Hydrocortison-ratiopharm® (FI); Hydrocortisonum® (PL); Hydrocortisyl® (IE); Hydrocortone® (AT, CH, GB, IE); Hydrocutan Salbe® (DE); Hydrocutan Tabletten® (DE); Hydroderm Aesca® (AT); Hydroderm® (AT, DE); Hydrogalen® (DE); Hydro Heumann® (DE); Hydrokortison CCS® (SE); Hydrokortison Galderma® (DK); Hydrokortison® (NO); Hydrokortison Nycomed® (DK); HydroVal® (CA); Hydro-Wolff® (DE); Hyproderm HC® (LU); Hysone® (AU); Hytisone® (HK); Kyypakkaus® (FI); LactiCare-HC® (CL, CR, DO, GT, HN, MX, PA, SV); Lactid HC® (AR); Lactisona® (ES, PT); Lemnis Fatty Cream HC® (NZ); Lergin® (SI); Linola Hydro® (DE); Locoid® (CA); Medrocil® (AR); Microsona® (AR); Mildison® (DK, FI, GB, IE, NL, NO, SE); Mildison Lipid® (DK, SE); Mildison Lipocream® (NZ); Mitocortyl® (FR); Nutracort® (BR, CR, DO, GT, MX, SV); Nutralona® (CL); Prevex® HC (CA); Prevex HC® (TH); Procutan® (ZA); Remederm HC® (DE); Sanatison® (DE); Sarna® HC (CA); Scalpicin Capilar® (ES); Scalpicin® (IT); Schericur® (AR, ES); Sirotamicin H.C.® (AR); Solu-Cortef® (CA, LU, PT, SI); Solu-Cortil® (AR); Stiefcortil® (AR, BR); Systral Hydrocort® (DE); Transderma H® (AR); Unicort® (CO); Uniderm® (DK, SE, SG); Vari-Hydrocortisone® (ZA); Westcort® (CA); Xyloproct® (NO)


A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com